{"pmid":32357975,"title":"Early intervention likely improves mortality in COVID-19 infection.","text":["Early intervention likely improves mortality in COVID-19 infection.","While some risk factors have been identified, the reasons for the disparities in disease progression with COVID-19 are unclear, with some patients developing progressive and severe disease while in others the course is benign. Given this sense of randomness, and in the absence of a definitive treatment, medical professionals can feel helpless. It is useful to remember how much can be done to affect the trajectory of illness, even without a 'magic bullet'. With evidence emerging that late presentation is directly associated with increased mortality, we make the case for increased vigilance in the community and earlier intervention.","Clin Med (Lond)","Goyal, Daniel K","Mansab, Fatma","Iqbal, Amir","Bhatti, Sohail","32357975"],"abstract":["While some risk factors have been identified, the reasons for the disparities in disease progression with COVID-19 are unclear, with some patients developing progressive and severe disease while in others the course is benign. Given this sense of randomness, and in the absence of a definitive treatment, medical professionals can feel helpless. It is useful to remember how much can be done to affect the trajectory of illness, even without a 'magic bullet'. With evidence emerging that late presentation is directly associated with increased mortality, we make the case for increased vigilance in the community and earlier intervention."],"journal":"Clin Med (Lond)","authors":["Goyal, Daniel K","Mansab, Fatma","Iqbal, Amir","Bhatti, Sohail"],"date":"2020-05-03T11:00:00Z","year":2020,"_id":"32357975","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.7861/clinmed.2020-0214","keywords":["covid-19","sars-cov-2","intervention","oxygen","treatment"],"topics":["Treatment"],"weight":1,"_version_":1666138495337365505,"score":9.490897,"similar":[{"pmid":32141624,"title":"Transmission dynamics of the COVID-19 outbreak and effectiveness of government interventions: A data-driven analysis.","text":["Transmission dynamics of the COVID-19 outbreak and effectiveness of government interventions: A data-driven analysis.","Using the parameterized susceptible-exposed-infectious-recovered model, we simulated the spread dynamics of coronavirus disease 2019 (COVID-19) outbreak and impact of different control measures, conducted the sensitivity analysis to identify the key factor, plotted the trend curve of effective reproductive number (R), and performed data fitting after the simulation. By simulation and data fitting, the model showed the peak existing confirmed cases of 59 769 arriving on 15 February 2020, with the coefficient of determination close to 1 and the fitting bias 3.02%, suggesting high precision of the data-fitting results. More rigorous government control policies were associated with a slower increase in the infected population. Isolation and protective procedures would be less effective as more cases accrue, so the optimization of the treatment plan and the development of specific drugs would be of more importance. There was an upward trend of R in the beginning, followed by a downward trend, a temporary rebound, and another continuous decline. The feature of high infectiousness for severe acute respiratory syndrome coronavirus 2(SARS-CoV-2) led to an upward trend, and government measures contributed to the temporary rebound and declines. The declines of R could be exploited as strong evidence for the effectiveness of the interventions. Evidence from the four-phase stringent measures showed that it was significant to ensure early detection, early isolation, early treatment, adequate medical supplies, patients' being admitted to designated hospitals, and comprehensive therapeutic strategy. Collaborative efforts are required to combat the novel coronavirus, focusing on both persistent strict domestic interventions and vigilance against exogenous imported cases.","J Med Virol","Fang, Yaqing","Nie, Yiting","Penny, Marshare","32141624"],"abstract":["Using the parameterized susceptible-exposed-infectious-recovered model, we simulated the spread dynamics of coronavirus disease 2019 (COVID-19) outbreak and impact of different control measures, conducted the sensitivity analysis to identify the key factor, plotted the trend curve of effective reproductive number (R), and performed data fitting after the simulation. By simulation and data fitting, the model showed the peak existing confirmed cases of 59 769 arriving on 15 February 2020, with the coefficient of determination close to 1 and the fitting bias 3.02%, suggesting high precision of the data-fitting results. More rigorous government control policies were associated with a slower increase in the infected population. Isolation and protective procedures would be less effective as more cases accrue, so the optimization of the treatment plan and the development of specific drugs would be of more importance. There was an upward trend of R in the beginning, followed by a downward trend, a temporary rebound, and another continuous decline. The feature of high infectiousness for severe acute respiratory syndrome coronavirus 2(SARS-CoV-2) led to an upward trend, and government measures contributed to the temporary rebound and declines. The declines of R could be exploited as strong evidence for the effectiveness of the interventions. Evidence from the four-phase stringent measures showed that it was significant to ensure early detection, early isolation, early treatment, adequate medical supplies, patients' being admitted to designated hospitals, and comprehensive therapeutic strategy. Collaborative efforts are required to combat the novel coronavirus, focusing on both persistent strict domestic interventions and vigilance against exogenous imported cases."],"journal":"J Med Virol","authors":["Fang, Yaqing","Nie, Yiting","Penny, Marshare"],"date":"2020-03-07T11:00:00Z","year":2020,"_id":"32141624","source":"PubMed","week":"202010|Mar 02 - Mar 08","doi":"10.1002/jmv.25750","keywords":["covid-19","sars-cov-2","seir","basic reproductive number","data fitting","data simulation","effective reproductive number","effectiveness","intervention","sensitivity analysis","transmission"],"e_drugs":["Arginine"],"topics":["Transmission","Prevention"],"weight":1,"_version_":1666138492759965696,"score":123.11592},{"pmid":32299148,"title":"Considerations for obesity, vitamin D, and physical activity amidst the COVID-19 pandemic.","text":["Considerations for obesity, vitamin D, and physical activity amidst the COVID-19 pandemic.","As the biomedical community races to disentangle the unknowns associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) - the virus responsible for causing coronavirus disease (COVID-19) - the link between diminished immune function and individuals with obesity raises important questions about the possibility for greater viral pathogenicity in this population. Increased adiposity may undermine the pulmonary microenvironment wherein viral pathogenesis and immune cell trafficking could contribute to a maladaptive cycle of local inflammation and secondary injury. A further challenge to those with obesity during the current pandemic may involve vitamin D deficiency/insufficiency. In the interest of personal and public health, we caution decision/policy makers alike not to pin all hope on a proverbial 'silver bullet.' Until further breakthroughs emerge, we should remember that modifiable lifestyle factors like diet and physical activity should not be marginalized. Decades of empirical evidence supports both as key factors promoting health and wellness.","Obesity (Silver Spring)","Carter, Stephen J","Baranauskas, Marissa N","Fly, Alyce D","32299148"],"abstract":["As the biomedical community races to disentangle the unknowns associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) - the virus responsible for causing coronavirus disease (COVID-19) - the link between diminished immune function and individuals with obesity raises important questions about the possibility for greater viral pathogenicity in this population. Increased adiposity may undermine the pulmonary microenvironment wherein viral pathogenesis and immune cell trafficking could contribute to a maladaptive cycle of local inflammation and secondary injury. A further challenge to those with obesity during the current pandemic may involve vitamin D deficiency/insufficiency. In the interest of personal and public health, we caution decision/policy makers alike not to pin all hope on a proverbial 'silver bullet.' Until further breakthroughs emerge, we should remember that modifiable lifestyle factors like diet and physical activity should not be marginalized. Decades of empirical evidence supports both as key factors promoting health and wellness."],"journal":"Obesity (Silver Spring)","authors":["Carter, Stephen J","Baranauskas, Marissa N","Fly, Alyce D"],"date":"2020-04-17T11:00:00Z","year":2020,"_id":"32299148","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1002/oby.22838","keywords":["body mass index","cardiopulmonary","inflammation","influenza","prevention"],"e_drugs":["Vitamin D"],"topics":["Prevention"],"weight":1,"_version_":1666138493270622208,"score":113.34327},{"pmid":32220033,"title":"Early antiviral treatment contributes to alleviate the severity and improve the prognosis of patients with novel coronavirus disease (COVID-19).","text":["Early antiviral treatment contributes to alleviate the severity and improve the prognosis of patients with novel coronavirus disease (COVID-19).","BACKGROUND: At present, the severity of patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been a focal point. METHODS: To assess the factors associated with severity and prognosis of patients infected with SARS-CoV-2, we retrospectively investigated the clinical, imaging and laboratory characteristics of confirmed 280 cases of novel coronavirus disease (COVID-19) from 20 January to 20 February 2020. RESULTS: The median age of patients in the mild group was 37.55 years, whilst that in the severe group was 63.04 years. The proportion of patients aged over 65 years in the severe group was significantly higher than that of the mild group (59.04% vs. 10.15%, P < 0.05). 85.54% of severe patients had diabetes or cardiovascular diseases, which was significantly higher than that of the mild group (51.81% vs. 7.11%, P = 0.025; 33.73% vs. 3.05%, P = 0.042). Patients in the mild group experienced earlier initiation of antiviral treatment (1.19 +/- 0.45 vs. 2.65 +/- 1.06 days in the severe group, P < 0.001). Our study showed that comorbidity, time from illness onset to antiviral treatment and age >=65 were three major risk factors for COVID-19 progression, whilst comorbidity and time from illness onset to antiviral treatment were two major risk factors for COVID-19 recovery. CONCLUSIONS: The elderly and patients with underlying diseases are more likely to experience a severe progression of COVID-19. It is recommended that timely antiviral treatment should be initiated to slow the disease progression and improve the prognosis.","J Intern Med","Wu, J","Li, W","Shi, X","Chen, Z","Jiang, B","Liu, J","Wang, D","Liu, C","Meng, Y","Cui, L","Yu, J","Cao, H","Li, L","32220033"],"abstract":["BACKGROUND: At present, the severity of patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been a focal point. METHODS: To assess the factors associated with severity and prognosis of patients infected with SARS-CoV-2, we retrospectively investigated the clinical, imaging and laboratory characteristics of confirmed 280 cases of novel coronavirus disease (COVID-19) from 20 January to 20 February 2020. RESULTS: The median age of patients in the mild group was 37.55 years, whilst that in the severe group was 63.04 years. The proportion of patients aged over 65 years in the severe group was significantly higher than that of the mild group (59.04% vs. 10.15%, P < 0.05). 85.54% of severe patients had diabetes or cardiovascular diseases, which was significantly higher than that of the mild group (51.81% vs. 7.11%, P = 0.025; 33.73% vs. 3.05%, P = 0.042). Patients in the mild group experienced earlier initiation of antiviral treatment (1.19 +/- 0.45 vs. 2.65 +/- 1.06 days in the severe group, P < 0.001). Our study showed that comorbidity, time from illness onset to antiviral treatment and age >=65 were three major risk factors for COVID-19 progression, whilst comorbidity and time from illness onset to antiviral treatment were two major risk factors for COVID-19 recovery. CONCLUSIONS: The elderly and patients with underlying diseases are more likely to experience a severe progression of COVID-19. It is recommended that timely antiviral treatment should be initiated to slow the disease progression and improve the prognosis."],"journal":"J Intern Med","authors":["Wu, J","Li, W","Shi, X","Chen, Z","Jiang, B","Liu, J","Wang, D","Liu, C","Meng, Y","Cui, L","Yu, J","Cao, H","Li, L"],"date":"2020-03-29T11:00:00Z","year":2020,"_id":"32220033","source":"PubMed","week":"202013|Mar 23 - Mar 29","doi":"10.1111/joim.13063","keywords":["antiviral treatment","coronavirus disease-19 (covid-19)","disease progression","prognosis","severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"],"topics":["Treatment"],"weight":1,"_version_":1666138492284960768,"score":96.96347},{"pmid":32445881,"title":"Arbidol/IFN-alpha2b Therapy for Patients With Corona Virus Disease 2019: A Retrospective Multicenter Cohort Study.","text":["Arbidol/IFN-alpha2b Therapy for Patients With Corona Virus Disease 2019: A Retrospective Multicenter Cohort Study.","The spread of COVID-19 is accelerating. At present, there is no specific antiviral drugs for COVID-19 outbreak. This is a multicenter retrospective cohort study of patients with laboratory-confirmed COVID-19 infection pneumonia from 3 hospitals in Hubei and Guangdong province, 141 adults (aged >/=18 years) without ventilation were included. Combined group patients were given Arbidol and IFN-alpha2b, monotherapy group patients inhaled IFN-alpha2b for 10-14 days. Of 141 COVID-19 patients, baseline clinical and laboratory characteristics were similar between combined group and monotherapy group, that 30% of the patients leucocytes counts were below the normal range and 36.4% of the patients experienced lymphocytopenia. The duration of viral RNA of respiratory tract in the monotherapy group was not longer than that in the combined therapy group. There was no significant differences between two groups. The absorption of pneumonia in the combined group was faster than that in the monotherapy group. We inferred that Arbidol/IFN - 2b therapy can be used as an effective method to improve the COVID-19 pneumonia of mild patients, although it helpless with accelerating the virus clearance. These results should be verified in a larger prospective randomized environment.","Microbes Infect","Xu, Ping","Huang, Jianping","Fan, Zhao","Huang, Wendi","Qi, Minghua","Lin, Xuwen","Song, Weidong","Yi, Li","32445881"],"abstract":["The spread of COVID-19 is accelerating. At present, there is no specific antiviral drugs for COVID-19 outbreak. This is a multicenter retrospective cohort study of patients with laboratory-confirmed COVID-19 infection pneumonia from 3 hospitals in Hubei and Guangdong province, 141 adults (aged >/=18 years) without ventilation were included. Combined group patients were given Arbidol and IFN-alpha2b, monotherapy group patients inhaled IFN-alpha2b for 10-14 days. Of 141 COVID-19 patients, baseline clinical and laboratory characteristics were similar between combined group and monotherapy group, that 30% of the patients leucocytes counts were below the normal range and 36.4% of the patients experienced lymphocytopenia. The duration of viral RNA of respiratory tract in the monotherapy group was not longer than that in the combined therapy group. There was no significant differences between two groups. The absorption of pneumonia in the combined group was faster than that in the monotherapy group. We inferred that Arbidol/IFN - 2b therapy can be used as an effective method to improve the COVID-19 pneumonia of mild patients, although it helpless with accelerating the virus clearance. These results should be verified in a larger prospective randomized environment."],"journal":"Microbes Infect","authors":["Xu, Ping","Huang, Jianping","Fan, Zhao","Huang, Wendi","Qi, Minghua","Lin, Xuwen","Song, Weidong","Yi, Li"],"date":"2020-05-24T11:00:00Z","year":2020,"_id":"32445881","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.micinf.2020.05.012","keywords":["2019-ncov","arbidol","covid-19","ifn-alpha2b","rna","pneumonia","treatment"],"locations":["Hubei","Guangdong"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1667600475793391616,"score":90.78012},{"pmid":32344310,"pmcid":"PMC7175905","title":"Respiratory conditions in coronavirus disease 2019 (COVID-19): Important considerations regarding novel treatment strategies to reduce mortality.","text":["Respiratory conditions in coronavirus disease 2019 (COVID-19): Important considerations regarding novel treatment strategies to reduce mortality.","A novel virus named 2019 novel coronavirus (2019-nCoV/SARS-CoV-2) causes symptoms that are classified as coronavirus disease (COVID-19). Respiratory conditions are extensively described among more serious cases of COVID-19, and the onset of acute respiratory distress syndrome (ARDS) is one of the hallmark features of critical COVID-19 cases. ARDS can be directly life-threatening because it is associated with low blood oxygenation levels and can result in organ failure. There are no generally recognized effective treatments for COVID-19, but treatments are urgently needed. Anti-viral medications and vaccines are in the early developmental stages and may take many months or even years to fully develop. At present, management of COVID-19 with respiratory and ventilator support are standard therapeutic treatments, but unfortunately such treatments are associated with high mortality rates. Therefore, it is imperative to consider novel new therapeutic interventions to treat/ameliorate respiratory conditions associated with COVID-19. Alternate treatment strategies utilizing clinically available treatments such as hyperbaric oxygen therapy (HBOT), packed red blood cell (pRBC) transfusions, or erthropoiesis-stimulating agent (ESA) therapy were hypothesized to increase oxygenation of tissues by alternative means than standard respiratory and ventilator treatments. It was also revealed that alternative treatments currently being considered for COVID-19 such as chloroquine and hydroxychloroquine by increasing hemoglobin production and increasing hemoglobin availability for oxygen binding and acetazolamine (for the treatment of altitude sickness) by causing hyperventilation with associated increasing levels of oxygen and decreasing levels of carbon dioxide in the blood may significantly ameliorate COVID-19 respiratory symptoms. In conclusion, is recommend, given HBOT, pRBC, and ESA therapies are currently available and routinely utilized in the treatment of other conditions, that such therapies be tried among COVID-19 patients with serious respiratory conditions and that future controlled-clinical trials explore the potential usefulness of such treatments among COVID-19 patients with respiratory conditions.","Med Hypotheses","Geier, Mark R","Geier, David A","32344310"],"abstract":["A novel virus named 2019 novel coronavirus (2019-nCoV/SARS-CoV-2) causes symptoms that are classified as coronavirus disease (COVID-19). Respiratory conditions are extensively described among more serious cases of COVID-19, and the onset of acute respiratory distress syndrome (ARDS) is one of the hallmark features of critical COVID-19 cases. ARDS can be directly life-threatening because it is associated with low blood oxygenation levels and can result in organ failure. There are no generally recognized effective treatments for COVID-19, but treatments are urgently needed. Anti-viral medications and vaccines are in the early developmental stages and may take many months or even years to fully develop. At present, management of COVID-19 with respiratory and ventilator support are standard therapeutic treatments, but unfortunately such treatments are associated with high mortality rates. Therefore, it is imperative to consider novel new therapeutic interventions to treat/ameliorate respiratory conditions associated with COVID-19. Alternate treatment strategies utilizing clinically available treatments such as hyperbaric oxygen therapy (HBOT), packed red blood cell (pRBC) transfusions, or erthropoiesis-stimulating agent (ESA) therapy were hypothesized to increase oxygenation of tissues by alternative means than standard respiratory and ventilator treatments. It was also revealed that alternative treatments currently being considered for COVID-19 such as chloroquine and hydroxychloroquine by increasing hemoglobin production and increasing hemoglobin availability for oxygen binding and acetazolamine (for the treatment of altitude sickness) by causing hyperventilation with associated increasing levels of oxygen and decreasing levels of carbon dioxide in the blood may significantly ameliorate COVID-19 respiratory symptoms. In conclusion, is recommend, given HBOT, pRBC, and ESA therapies are currently available and routinely utilized in the treatment of other conditions, that such therapies be tried among COVID-19 patients with serious respiratory conditions and that future controlled-clinical trials explore the potential usefulness of such treatments among COVID-19 patients with respiratory conditions."],"journal":"Med Hypotheses","authors":["Geier, Mark R","Geier, David A"],"date":"2020-04-29T11:00:00Z","year":2020,"_id":"32344310","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1016/j.mehy.2020.109760","keywords":["2019-ncov","epo","pulmonary","sars-cov-2"],"e_drugs":["Hydroxychloroquine","Chloroquine","Carbon Dioxide"],"topics":["Treatment"],"weight":1,"_version_":1666138495790350336,"score":88.26664}]}